In the News

News & Publications

  • Filter by type

January 3, 2024 | Press Release

LONDON, Jan. 03, 2024 (GLOBE NEWSWIRE) — Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing opelconazole for patients suffering […]

October 16, 2023 | Press Release

LONDON – October 16, 2023 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients […]

June 8, 2023 | Press Release

LONDON, June 08, 2023 — Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering […]

December 6, 2022 | Press Release

Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic […]

December 21, 2021 | Press Release

Pulmocide Ltd. (“the Company”), a late-stage biopharmaceutical company focused on the development of a novel inhaled azole therapy for patients […]

September 16, 2021 | Press Release

Pulmocide raised $92 million in Series C funds in May 2021 to fund a registration program for opelconazole in patients […]

May 27, 2021 | Press Release

– Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and […]

March 11, 2021 | Press Release

London, UK, 11 March 2021 – Pulmocide Ltd., which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, […]

October 26, 2020 | Publications & Presentations

London, UK, 26 October 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives initially for targeted treatment of life-threatening […]

Scroll to Top